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Background-—Identiﬁcation of genetic markers of antihypertensive drug responses could assist in individualization of hypertension
treatment.
Methods and Results-—We conducted a genome-wide association study to identify gene loci inﬂuencing the responsiveness of
228 male patients to 4 classes of antihypertensive drugs. The Genetics of Drug Responsiveness in Essential Hypertension
(GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,
hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order. Replication analyses were performed in 4 studies
with patients of European ancestry (PEAR Study, N=386; GERA I and II Studies, N=196 and N=198; SOPHIA Study, N=372). We
identiﬁed 3 single-nucleotide polymorphisms within the ACY3 gene that showed associations with bisoprolol response reaching
genome-wide signiﬁcance (P<59108); however, this could not be replicated in the PEAR Study using atenolol. In addition, 39
single-nucleotide polymorphisms showed P values of 105 to 107. The 20 top-associated single-nucleotide polymorphisms were
different for each antihypertensive drug. None of these top single-nucleotide polymorphisms co-localized with the panel of >40
genes identiﬁed in genome-wide association studies of hypertension. Replication analyses of GENRES results provided suggestive
evidence for a missense variant (rs3814995) in the NPHS1 (nephrin) gene inﬂuencing losartan response, and for 2 variants
inﬂuencing hydrochlorothiazide response, located within or close to the ALDH1A3 (rs3825926) and CLIC5 (rs321329) genes.
Conclusions-—These data provide some evidence for a link between biology of the glomerular protein nephrin and antihypertensive
action of angiotensin receptor antagonists and encourage additional studies on aldehyde dehydrogenase–mediated reactions in
antihypertensive drug action. ( J Am Heart Assoc. 2015;4:e001521 doi: 10.1161/JAHA.114.001521)
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B y 2010, elevated blood pressure (BP) became theleading risk factor of disease burden on a global
basis.1 The insidious nature of hypertension is substantiated
by its increasing prevalence, its mostly asymptomatic
nature, and its poor drug control. Indeed, globally more
than 1 billion people suffer from hypertension, but only 40%
to 50% of those on therapy reach the targets of treat-
ment.2,3 This is most unfortunate since even a small
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lowering of elevated BP results in signiﬁcant reduction of
cardiovascular events.
Family, twin, and adoption studies have suggested that
heritability accounts for 30% to 50% of interindividual variation
of BP.4–6 Recent extensive genome-wide association studies
have revealed >40 genetic loci associated with essential
hypertension,4–6 but even combined they account for only 2%
of variability of BP, and no variant is of proven clinical value in
guiding antihypertensive drug treatment. Until 2009, phar-
macogenomic studies of hypertension suffered from narrow
selection of candidate genes, small sample sizes, and weak-
nesses in study design.7 In subsequent studies, suggestive but
inconsistent associations were reported when panels of gene
variants selected by data from the hypertension genome-wide
association studies were screened in the Genetics of Drug
Responsiveness in Essential Hypertension (GENRES)8 and
Pharmacogenomic Evaluation of Antihypertensive Responses
(PEAR)9 cohorts. Recently, the ﬁrst applications of genome-
wide association studies principles in pharmacogenomics of
hypertension have taken place,10–12 but there is still a need for
controlled randomized studies with adequate replication of
data using results from other laboratories.
The GENRES study is a randomized, double-blind, cross-
over, placebo-controlled study of 228 hypertensive men who
received 4 different classes of antihypertensive drugs (a
diuretic, b-blocker, calcium-channel blocker, and angiotensin
receptor antagonist), each as a monotherapy, in a rotational
manner.13 Both ofﬁce (OBP) and 24-hour ambulatory (ABP)
blood pressure responses were measured. We here report
genome-wide analysis of association of 0.7M single-nucleo-
tide polymorphisms (SNPs) to the different antihypertensive
drug responses, and also provide results from attempts to
replicate ﬁndings using meta-analysis data from the PEAR,14
Genetic Epidemiology of Responses to Antihypertensives
(GERA) I,15 GERA II,10 and Study of the Pharmacogenomics
in Italian hypertensive patients treated with the Angiotensin
receptor blocker losartan (SOPHIA)16 studies.
Methods
Study Participants
The design of the GENRES Study with initial clinical and
biochemical data has been described previously.13,17 In brief, a
total of 313 moderately hypertensive Finnish men (aged 35 to
60 years) were initially screened.13 Inclusion criteria were
diastolic BP ≥95 mm Hg in repeated measurements or use of
antihypertensive medication. Exclusion criteria were use of 3 or
more antihypertensive drugs, secondary hypertension, or
signiﬁcant comorbidity. There was no evident heart, cerebro-
vascular, liver, pulmonary, or kidney disease, and no patient had
drug-treated diabetes. No participant had signs of abuse of
alcohol or drugs. Each study participant received losartan
50 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg, and
amlodipine 5 mg daily, each as a monotherapy in randomized
order for 4 weeks. The study started with a 4-week run-in
placebo period, and all 4 drug treatment periodswere separated
by 4-week placebo periods. Twenty-four-hour ABP readings
were recorded at the end of each treatment period with a device
equipped with a QRS complex detector and a position sensor
(Diasys Integra; Novacor, Rueil-Malmaison, France); in addition,
OBP measurements were carried out with repeated measure-
ments after a 30-minute rest in the sitting position using a
semiautomatic oscillometric device. In this study, ABP
responses to the 4 monotherapies were analyzed. The 228
subjects who were successfully genotyped and had ABP
response data from at least 1 drug treatment period are
included in this study. Of these subjects, 212, 204, and 177 had
ABP response data from 2, 3, and 4 drug treatments,
respectively.
The clinical part of the GENRES study was conducted in
accordance with the Declaration of Helsinki and Guidelines for
Good Clinical Practice (1996) at Helsinki University Central
Hospital between years 1999 and 2004. The study was
approved by the Ethical Committee of Helsinki University
Central Hospital and the National Agency for Medicines of
Finland. All subjects gave signed informed consent before any
study-related activities.
PEAR is a study of mild--to--moderate hypertensives, with
diastolic OBP >90 mm Hg (and ≤110 mm Hg) and diastolic
home BP >85 mm Hg. The details of the study design have
been described previously.14 In brief, the patients had no
history of cardiovascular disease or diabetes and were
between the ages of 17 and 65 years. After an average
washout period of 28 days, they had baseline data collected,
which included measurement of home, ofﬁce, and 24-hour
ABP, along with collection of biological samples. They were
then randomized to atenolol 50 mg daily or hydrochlorothi-
azide 12.5 mg daily. Following 3 weeks on this dose, those
with BP >120/70 mm Hg had the dose doubled, followed by
an additional 6 weeks of treatment, after which BP data were
collected along with biological samples. The 24-hour ABP data
were used for this analysis. Only subjects of European
ancestry were included in the present study.
For each of the GERA I and II studies, 300 whites (in
Rochester, MN) and 300 African Americans (in Atlanta, GA)
were enrolled.18,19 The participants had uncomplicated
primary hypertension, stage 1 to 2, and were 30 to 59.9 years
of age. They were instructed to discontinue previous antihy-
pertensive medications for ≥4 weeks. Once stable elevation
of the BP was achieved (diastolic OBP ≥90 mm Hg), the study
drug was administered orally: hydrochlorothiazide 25 mg daily
for 4 weeks or candesartan 16 mg daily for 2 weeks followed
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drug-free and drug-treatment periods, 3 readings of BP were
made by a trained assistant after the participant had been
seated quietly for at least 5 minutes. The difference between
averages of the second and third diastolic BP readings taken
before and at the end of drug treatment was calculated as
the BP response. Only subjects of European ancestry were
included in the present study.
The SOPHIA Study is a study of mild-to-moderate, asymp-
tomatic, never-treated hypertensive patients (85% of partic-
ipants), or patients out of treatment for at least 6 months
(15% of participants).16 At the screening visit (week -8),
participants ranging 18 to 59 years of age had to display
systolic OBP from 140 to 179 mm Hg and diastolic OBP from
90 to 109 mm Hg. At each visit, OBP was measured 3 times,
using a certiﬁed electronic device, with the subject in the
sitting position after 5 minutes’ rest. During a run-in period of
8 weeks, the participants followed a diet program that
provided 100 to 140 mEq of sodium and 50 to 70 mEq of
potassium daily to minimize the lifestyle differences. At the
end of this period, 50 mg/day of losartan as open-label was
prescribed for 4 weeks.
Genotyping Methods
The DNA samples of 228 GENRES study subjects were
successfully genotyped (success rates >99%) at the Institute
for Molecular Medicine Technology Centre, University of
Helsinki using the Illumina HumanOmniExpress-12 BeadChip
(Illumina, Inc, San Diego, CA). The genotypes (NCBI build 37,
hg19) were called and quality controlled using GenomeStudio v.
2011.1 software (Illumina, Inc) and in-house-developed data-
base tools. Further quality steps, including identity-by-state
clustering and gender check, were performed using Plink
software and PLINK v1.07 toolset.20 Of the total of 709 357
genotyped autosomal SNPs, 707 658 passed these quality-
control steps. After this, SNPs with Hardy-Weinberg equilibrium
P value <19105 (393 SNPs) and minor allele frequency <0.01
(75 421 SNPs) were excluded, which resulted in 631 844
autosomal SNPs that were used for analysis.
DNA samples from PEAR were genotyped using Illumina
Human Omni1-Quad BeadChip (Illumina) as previously
described.11 DNA samples from GERA I and II study partic-
ipants were genotyped using the Affymetrix GeneChip Human
Mapping 6.0 Array Sets.10,11 SOPHIA samples were geno-
typed using the Illumina Human1M-Duo array (Illumina) and
imputed using MACH software and the HapMap CEU haplo-
types (release 22) as reference.
Statistical Analyses
As the ﬁrst step of the present study, systolic (ASBP) and
diastolic (ADBP) 24-hour ambulatory blood pressure
responses to each of the 4 monotherapies were analyzed
separately in the GENRES Study (discovery sample). The BP
response was calculated as BP after 4 weeks’ drug treatment
minus mean BP after placebo periods. The mean BP level of all
(up to 4) placebo periods, as opposed to the 1 preceding
placebo period, was used as the baseline level to reduce BP
variation. The approach was supported by several analyses.
First, the BP responses to study drugs showed clearly lower
variation when mean of all placebo periods was used as the
baseline level (Table S1). Second, compared with the other
drugs, amlodipine seemed to have a small carry-over effect
(1.5/0.5 mm Hg) based on placebo BP levels 4 weeks
after amlodipine treatment (Table S2). The randomized cross-
over design and the use of all placebo periods as the baseline
level eliminates any systematic effect of this ﬁnding on the
results. In addition, the effect was probably even smaller after
an additional 4 weeks when BP response to the next study
drug was assessed. Third, the higher variation of placebo BP
levels when only 1 placebo period was used can be seen in
Table S2 as higher SDs. Finally, the preceding study treatment
and the order of the drug treatment periods had no effect on
BP response to any of the study drug when they were tested
with regression analysis (GLM Univariate procedure of IBM
SPSS Statistics program, version 19).
For the genome-wide analyses, ASBP and ADBP response
residuals were generated using IBM SPSS Statistics program
and stepwise linear regression. The following covariates were
tested with P<0.10 as an inclusion condition: corresponding
Table 1. Characteristics of the Subjects From the Genetics of
Drug Responsiveness in Essential Hypertension (GENRES) Study
Number of subjects 228
Age, y 50.6 (6.4)
Body mass index, kg/m2 26.7 (2.7)
ABP during placebo periods (systolic/
diastolic, mm Hg)
135 (10)/93 (6)
OBP during placebo periods (systolic/
diastolic, mm Hg)
152 (13)/100 (7)
ABP responses (systolic/diastolic, mm Hg)
Amlodipine (N=205) 7.4 (7.2)/4.9 (4.0)
Bisoprolol (N=207) 11.1 (6.2)/8.3 (4.2)
Hydrochlorothiazide (N=206) 4.8 (6.3)/1.7 (4.1)
Losartan (N=203) 9.1 (6.7)/6.1 (4.7)
dU-sodium, mmol/24 h 173 (70)
Fasting serum glucose, mmol/L 5.4 (0.6)
Serum creatinine, mmol/L 86 (13)
Subjects with genome-wide genetic data and ambulatory blood pressure recordings after
at least 1 antihypertensive monotherapy are included. All subjects were males. Data are
presented as mean (SD). ABP indicates 24-h ambulatory blood pressure; dU, daily urinary















DOI: 10.1161/JAHA.114.001521 Journal of the American Heart Association 3





Figure 1. Manhattan plots from the genome-wide association analysis of the ambulatory blood pressure responses using
an additive model. (A) Losartan, systolic; (B) losartan, diastolic; (C) bisoprolol, systolic; (D) bisoprolol, diastolic; (E)















DOI: 10.1161/JAHA.114.001521 Journal of the American Heart Association 4





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DOI: 10.1161/JAHA.114.001521 Journal of the American Heart Association 5
Pharmacogenomics of Antihypertensive Drugs Hiltunen et al
placebo ABP (mean of all periods), age, earlier use of
antihypertensive medication (coded as 0/1), current smoking
(coded as 0/1), body mass index, daily urinary sodium
excretion after the ﬁrst placebo period, and serum creatinine
level after the ﬁrst placebo period. For non-normally distrib-
uted covariates, normalized values were used. The covariates
selected for calculation of BP response residuals (in mm Hg)
for each study drug are listed in Table S3.
The genome-wide association analysis was done using
covariate-adjusted BP responses and linear regression under
an additive genetic model with program PLINK.20 For each of
the 4 study drugs, we report here the 20 genetic loci with
the lowest P values based on either ASBP or ADBP responses.
P values <59108 were considered as signiﬁcant at the
genome-wide level.
In the second step, replication analyses of the 20 best loci
associated with losartan, bisoprolol, and hydrochlorothiazide
responses were carried out using the data from PEAR, GERA I,
GERA II, and SOPHIA studies. In each case, the analyses were
conﬁned to study participants of European ancestry only, and
age, gender, baseline BP, and principal components to
account for ancestry were used as covariates. Accordingly,
we replicated losartan/GENRES data using losartan/SOPHIA
and candesartan/GERA II data, bisoprolol/GENRES data using
atenolol/PEAR data, and hydrochlorothiazide/GENRES data
using both hydrochlorothiazide/PEAR and hydrochlorothia-
zide/GERA I data. Successful replication was deﬁned as
P values below the Bonferroni-corrected level of 2.59104
(number of individual tests: 99 SNPs in 5 replication study
analyses9SBP+DBP responses=198) and the same direction
of effect. Suggestive replication was deﬁned as P values
<0.05 and the same direction of effect.
As the third step, meta-analyses of the top 20 GENRES 24-
hour ambulatory blood pressure response SNPs in all available
studies were performed using inverse-variance model with
ﬁxed effects in METAL.21 We deﬁned signiﬁcant results as
P values <59108. In addition, P values <19105 were
considered to represent a suggestive association.
Results
Study Subjects
Principal demographic and clinical data from the subjects of
the GENRES Study are summarized in Table 1. The patients
were all males, had a slightly elevated body mass index (none
had body mass index >32 kg/m2) and a moderate hyperten-
sion (mean OBP 152/100 mm Hg). No patient had drug-
treated diabetes or reduced kidney glomerular ﬁltration rate.
The BP reductions, as assessed by the ABP measurements,
ranged from 4.8/1.7 mm Hg (hydrochlorothiazide) to 11.1/
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doses of antihypertensive drugs, and no attempt was made to
use equipotent doses.
First Step: Genome-Wide Association Analyses in
GENRES
Manhattan plots providing genome-wide associations of
630 000 SNPs with the antihypertensive responses to
losartan, bisoprolol, amlodipine, and hydrochlorothiazide are
illustrated in Figure 1. Three SNPs on chromosome 11
(rs2514036, rs948445, and rs2514037) provided evidence
for association reaching genome-wide signiﬁcance for ASBP
response to bisoprolol (Figure 1C and Table 2). These 3 SNPs
map within the coding and regulatory regions of ACY3, coding
for aminoacylase III. Altogether, 42 SNPs in 31 distinct
regions were identiﬁed having at least 1 SNP associated with
the treatment response at P≤19105 (Figure 1 and Tables 2
through 5).
The quantile-quantile plots (Figure 2) show little evidence
for genomic inﬂation and provide some support for the
existence of signiﬁcant associations with genomic loci
inﬂuencing responsiveness to losartan and bisoprolol.
The strongest associations for the 24-hour ABP responses
to the 4 different drug responses are listed in Tables 2
through 5. In each case, 20 loci with the lowest P values for
either ASBP or ADBP responses are indicated. For each locus
listed, there was a remarkable congruence between the
direction and relative extent of the systolic and diastolic BP
lowering. None of the top 20 loci were shared between 2 or
more drugs.
Second Step: Replication Analyses Using
Individual Pharmacogenomics Studies
We carried out replication analyses of the top 20 signiﬁcant
associations with each antihypertensive response noted in the
GENRES study, using data from 4 available studies: SOPHIA
(losartan responses compared to those in GENRES), GERA II
(candesartan responses, compared to losartan responses in
GENRES), PEAR (atenolol responses, compared to bisoprolol
responses in GENRES), and GERA I+PEAR (hydrochlorothia-
zide responses in all 3 studies). The participants of the
replication studies are described in Table 6. Note that while
the data from the GENRES and PEAR studies were based on
ABP recordings, OBP measurements were used in SOPHIA,
GERA I, and II. Composite results from these replication
analyses are listed in Tables 7 through 9. Two SNPs analyzed
in GENRES were not available in the replication material GERA
II (losartan/candesartan responses, Table 7) and 3 SNPs
were not available in GERA I (hydrochlorothiazide responses,
Table 9). Two ﬂanking SNPs were included in the replication
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responses to amlodipine could not be replicated in this
collaborative study.
Of the 60 SNPs with the strongest associations to
losartan, bisoprolol, or hydrochlorothiazide responses in
GENRES (Tables 2, 3 and 5), no SNP reached the Bonferron-
i-corrected level of signiﬁcance (2.59104). Only 1 SNP
(rs3814995 on chromosome 19) emerged that gave a 2-sided
P value <0.05 (suggestive signiﬁcance level), with the same
direction of BP effect, for both systolic and diastolic blood
pressure responses to a particular drug in 2 other studies
(Table 7). Accordingly, rs3814995 was associated with
systolic (P=2.09105) and diastolic (P=5.19104) BP
responses to losartan in GENRES, with systolic (P=0.03)
and diastolic (P=0.02) BP responses in GERA II, and diastolic
BP responses (P=0.03) in SOPHIA (Table 7); there was a trend
toward association for systolic BP response in SOPHIA
(P=0.19). The SNP rs3814995 corresponds to a Glu117Lys
missense mutation in the NPHS1 gene coding for the protein
nephrin.
Third Step: Meta-Analyses Based on GENRES,
PEAR, GERA I, GERA II, and SOPHIA Data
A meta-analysis employing inverse-variance model with ﬁxed
effects was carried out using SNP data from GENRES, GERA I,
GERA II, PEAR, and SOPHIA studies (Table 10). P values
<19105 were considered to indicate a suggestive associa-
tion; no SNP reached the genome-wide level of signiﬁcance
(59108).
Of the top 20 SNPs associated with losartan responses
in the GENRES Study, rs4953045 on chromosome 2 was
associated with BP response (P=5.19107) and rs12814605
on chromosome 12 with diastolic BP response (P=6.49106)
in the meta-analysis utilizing responses to losartan in SOPHIA
and candesartan in GERA II (Tables 10 and 11). The closest
gene to the intergenic SNP rs4953045 is LRPPRC, which is
located 46 kbp apart from it and codes for mitochondrial
leucine-rich PPR motif-containing protein. rs12814605 is
likewise an intergenic variant, located approximately 100 kb
apart from the closest protein-coding genes AVPR1A (argi-
nine vasopressin receptor 1A) and PPM1H (Mg2+/Mn2+
dependent protein phosphatase 1H). However, the slightly
higher P value for this SNP in the meta-analysis than in the
discovery study (Table 10) renders the signiﬁcance of this
ﬁnding uncertain.
Next, a meta-analysis of the 20 SNPs with the highest
association scores with bisoprolol responses in GENRES was
performed in conjunction with the PEAR Study, using 24-hour
ABP responses to atenolol for comparison (Tables 10 and
12). Two SNPs on chromosome 13, rs7984003 (P=7.89
107) and rs2765115 (P=3.69106) showed suggestive
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studies were analyzed. Two pseudogenes (PTMAP and
GYG1P2) but no obvious protein-coding gene candidates are
located in the vicinity of rs7984003. Of the protein-coding
genes, SPATA13 coding for spermatogenesis-associated pro-
tein 13 lies closest (24 kbp) to rs2765115. A corresponding
meta-analysis of DBP responses to bisoprolol revealed an
association to rs7268800 (P=8.69107), which is an inter-
genic polymorphism, with 2 long intergenic non-protein
coding RNA species but no apparent candidate genes in its
vicinity.
Finally, we carried out a similar meta-analysis with the
hydrochlorothiazide response data, using 24-hour ABP
responses in PEAR and OBP responses in GERA I for
comparison (Tables 10 and 13). rs3825926 on chromosome
15 was found to associate with systolic BP responses
(P=5.69106; GERA I data lacking). This SNP is located in
the intron of the ALDH1A3 gene coding for aldehyde
dehydrogenase 1 family member A3, and is 14 kbp apart
from the LRRK1 gene coding for leucine-rich repeat kinase 1.
A corresponding meta-analysis of diastolic BP responses
revealed 3 suggestive associations to 3 SNPs (Table 10).
rs4867623 is an intronic variant of KCNIP1 coding for
potassium (Kv) channel interacting protein 1; however, a
higher P value was obtained in the meta-analysis than in the
discovery sample (Table 10). rs321329 and rs321320 are 2
adjacent intergenic variants on chromosome 6, lying 90 kbp
of RUNX2 encoding the runt-related transcription factor 2 and
145 kb from CLIC5 encoding the chloride intracellular
channel 5.
Discussion
The majority of the pharmacogenomic studies on essential
hypertension carried out until now suffer from weaknesses in
their design.7 The GENRES Study represents a careful attempt
to avoid some of the most important problems. Accordingly,
this study is prospective, placebo-controlled, and rotational in
nature, implying that every test subject received 4 different
antihypertensive drugs as a 4 weeks0 monotherapy in a
randomized order, with 4 intervening 4 weeks0 placebo
periods. The use of the mean of 4 placebo periods increases
the accuracy of the estimation of baseline BP levels. The
performance of the GENRES study has been validated by a
number of observations. For example, the within-subject
resemblance of BP responses, as analyzed by pairwise
correlation matrixes, was found to be highest for responses
to bisoprolol and losartan (r=0.32 to 0.39), followed by
responses to amlodipine and hydrochlorothiazide (r=0.20 to
0.35), as would be expected.13 In addition, plasma renin
activity was positively correlated with BP responses to
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Figure 2. Quantile-quantile plots from the genome-wide association analysis of the ambulatory blood
pressure responses using an additive model. Single-nucleotide polymorphisms with minor allele frequency
<0.01 are excluded. (A) Losartan, systolic; (B) losartan, diastolic; (C) bisoprolol, systolic; (D) bisoprolol,
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0.03 to 0.17), and negatively with BP responses to hydro-
chlorothiazide (P values 0.01 to 0.07).17
There are several important limitations in the present
study. First, an obvious methodological limitation of the
GENRES study is the sample size of 228 individuals, resulting
in insufﬁcient power to detect effect sizes of 0.5 to 1 mm Hg,
characteristic of gene loci revealed in genome-wide associ-
ation studies of complex diseases. For example, we calculated
that in order to reach a power of 80% to detect an
antihypertensive response in GENRES, an effect size of
4 mm Hg is needed for a SNP with a minor allele frequency of
0.30. It should be noted, however, that in carefully controlled
pharmacogenetic studies, common polymorphisms with small
effects on BP levels may well have larger effects on BP
responsiveness. Second, the GENRES study included only
males with mild-to-moderate hypertension. Third, since equi-
potent drug effects were not designed to be reached, less
variability in responses to certain drugs may have affected our
data. Fourth, it is to be emphasized that while ABP
measurements were used in GENRES and PEAR, OBP
measurements were carried out in SOPHIA, GERA I, and
GERA II, which may have affected the meta-analysis data.
Even using the strictly controlled experimental conditions
in GENRES, we failed to identify pharmacogenomic associa-
tions of genome-wide signiﬁcance (P<59108), with the
exception of 3 SNPs (rs2514036, rs948445, and rs2514037)
reaching this value for bisoprolol responses. In fact, we
consider this lack of stronger associations as the most
signiﬁcant ﬁnding of our study, because it emphasizes the
importance of even larger samples of patients in studies with
similar strict design. Furthermore, it is of note that upon
listing of 80 different SNPs (20 for each drug, Tables 2
through 5) showing the strongest associations to drug
responses, we failed to identify any SNP common to more
than a single drug class, supporting the notion that the
genomic pathways regulating the BP-lowering mechanisms of
different classes of antihypertensive drugs are speciﬁc to
each class of drugs.
A meta-analysis using losartan response data from the
GENRES and SOPHIA studies and candesartan data from the
GERA II study revealed 2 gene loci of potential interest.
rs4953035 showing association with systolic BP responses is
located 46 kbp from LRPPRC coding for mitochondrial
leucine-rich PPR motif-containing protein that is expressed in
a variety of tissues, including the heart and kidney. There
were also other SNPs within or close to LRPPRC that showed
a signiﬁcant association (Table 3). Another gene of note,
PPM1B coding for Mg2+/Mn2+ dependent protein phospha-
tase, lies 126 kb from rs4953035. This gene may be involved
in the cell cycle and is richly expressed (eg, in the heart).
Recent data indicate that the phosphatase coded by PPB1B
selectively modulates PPAR activity.22
In addition, based on ranking of strengths of associations
of the various drug responses in GENRES and available
Table 6. Description of Subjects in Replication Studies
PEAR PEAR GERA I GERA II SOPHIA
Treatment Atenolol HCTZ HCTZ Candesartan Losartan
Blood pressure measurement method Ambulatory Ambulatory Office Office Office
Number of subjects in replication analyses 193 193 196 198 372
Women, N (%) 85 (44%) 80 (42%) 84 (43%) 98 (49%) 92 (25%)
Age, y 50.09.4 50.69.1 48.67.3 49.16.8 45.77.4
Body mass index, kg/m2 30.15.4 30.24.9 31.35.6 29.93.9 26.92.9
Baseline systolic blood pressure, mm Hg 13810 13911 14313 14713 1497
Baseline diastolic blood pressure, mm Hg 878 879 966 955 974
Blood pressure responses
Atenolol, systolic response, mm Hg 14.2 10.6
Atenolol, diastolic response, mm Hg 10.67.9
HCTZ, systolic response, mm Hg 8.410.1 10.913.0
HCTZ, diastolic response, mm Hg 4.57.2 6.38.8
Candesartan, systolic response, mm Hg 18.414.7
Candesartan, diastolic response, mm Hg 13.410.2
Losartan, systolic response, mm Hg 11.89.1
Losartan, systolic response, mm Hg 8.86.2
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replication studies, we found that 1 particular SNP,
rs3814995, was signiﬁcantly associated with responses to
angiotensin receptor antagonists in the same direction in 3
separate studies. It is of note that even meta-analysis of the
rs3814995 data indicated P values close to the 1.09105
(Table 11). This missense variant (NM_004646.3:c.349G>A)
maps within the coding region of the NPHS1 gene and causes
an amino acid substitution of glutamic acid to lysine
(p.Glu117Lys) in the nephrin protein. The amino acid is
conserved and the change is predicted to be probably
damaging by PolyPhen2 (score: 0.999). The variant is
relatively common, with a higher minor allele frequency in
populations of European origin (0.30) compared to African
Americans (0.09) (Exome Variant Server, http://evs.gs.wash-
ington.edu/EVS/). Nephrin is the principal structural protein
of the glomerular podocytes, and mutations of NPHS1 result
in the congenital nephrotic syndrome of the Finnish type.23–25
Increased angiotensin II levels have been shown to result in
decrease of renal nephrin expression in a hypertensive rat
model.26 Interestingly, angiotensin blockers irbesartan27 and
valsartan28 have been shown to attenuate the decrease of
nephrin levels and to retard the development of albuminuria in
diabetic spontaneously hypertensive rats. The p.Glu117Lys
variant does not seem to associate with diabetic proteinuria
or end-stage renal disease in type 1 diabetic patients,
although carriers of the minor allele had a later onset of
diabetes than those with the wild-type allele.29 Collectively,
the present and previous ﬁndings should justify additional
studies using samples and data from large long-term clinical
trials in which nephrin Glu117Lys genotypes are related to
blood pressure responses to angiotensin receptor antagonists
and to cardiovascular events.
When bisoprolol data were analyzed in the GENRES
material only, we obtained the highest P values with
genome-wide signiﬁcance (2.09108, 2.19108, and
4.19108) for the tightly linked nearby SNPs rs2514036,
rs948445, and rs2514037 present on chromosome 11.
rs2514036 is an upstream regulatory region variant of
ACY3, encoding aminoacylase III, while rs2514037 is an
intronic variant of ACY3. rs948445, a missense variant
mapping within the coding region of the ACY3 gene, causes
an amino acid substitution p.Arg8Gln, which is predicted by
PolyPhen2 to be benign. There appears to be no data solidly
linking ACY3 to regulation of blood pressure. It is known to be
abundantly expressed in kidney proximal tubules, where it
may have role in deacetylating mercapturic acids, and to
lesser extent in other tissues including brain and heart.30
Although b-adrenergic receptors may be more abundant in
epithelial cells of distal than proximal parts of the nephron (for
review, see Ref. [31]), cultured proximal tubular cells obtained
from animal models have been reported to contain b-1- and b-
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Table 8. Replication Analysis of the Best GENRES Bisoprolol 24-H Ambulatory Blood Pressure Response SNPs With Ambulatory
24-H Blood Pressure Responses to Atenolol in PEAR
Rank in GENRES SNP Chr Position (Build 37)
Replication Results From PEAR (N=192 to 193)
CA/NCA CAF SBP/DBP b P Value Direction of Replication
1 rs2514036 11 67 415 054 C/T 0.18 SBP 0.7 0.58 Opposite
DBP 0.5 0.56 Opposite
2 rs7268800 20 38 580 738 G/A 0.37 SBP 0.5 0.61 Same
DBP 0.9 0.14 Same
3 rs12967284 18 12 532 098 T/C 0.34 SBP 0.1 0.90 Same
DBP 0.2 0.75 Same
4 rs4357510 1 192 612 394 A/C 0.06 SBP 1.5 0.37 Opposite
DBP 1.0 0.35 Opposite
5 rs2506143 10 33 468 169 G/A 0.17 SBP 1.3 0.28 Same
DBP 0.9 0.26 Same
6 rs2029870 6 164 888 366 A/G 0.21 SBP 0.6 0.61 Same
DBP 0.2 0.84 Opposite
7 rs7984003 13 82 866 573 T/C 0.18 SBP 2.1 0.07 Same
DBP 0.5 0.52 Same
8 rs11777699 8 6 714 699 G/A 0.45 SBP 0.0 0.99 Same
DBP 0.2 0.75 Opposite
9 rs10519585 5 118 676 529 C/T 0.35 SBP 0.2 0.79 Same
DBP 0.3 0.63 Opposite
10 rs6501061 16 8 092 171 C/T 0.04 SBP 1.4 0.55 Same
DBP 0.7 0.65 Same
11 rs16918900 8 54 147 242 T/C 0.04 SBP 0.1 0.97 Opposite
DBP 0.6 0.67 Opposite
12 rs2194860 4 109 948 511 A/G 0.16 SBP 0.2 0.87 Same
DBP 0.3 0.72 Opposite
13 rs2765115 13 24 529 399 G/A 0.13 SBP 2.2 0.14 Same
DBP 0.4 0.71 Same
14 rs17642669 5 140 628 277 G/A 0.05 SBP 1.5 0.48 Same
DBP 0.4 0.80 Opposite
15 rs7895038 10 2 432 266 T/C 0.47 SBP 0.0 0.98 Opposite
DBP 0.3 0.60 Same
16 rs150210 21 19 362 312 C/T 0.25 SBP 1.1 0.30 Opposite
DBP 0.6 0.43 Opposite
17 rs10910862 1 181 045 421 T/C 0.06 SBP 0.2 0.93 Opposite
DBP 0.1 0.96 Same
18 rs2148117 10 27 213 946 C/T 0.05 SBP 0.6 0.80 Same
DBP 0.2 0.88 Opposite
19 rs1150433 3 163 653 210 T/C 0.21 SBP 0.4 0.71 Opposite
DBP 0.0 0.98 Same
20 rs969981 17 63 818 989 T/C 0.23 SBP 0.2 0.85 Opposite
DBP 0.1 0.86 Opposite
The loci are listed in the order of their rank in GENRES. All SNPs in this table were genotyped. CA indicates coded allele; CAF, coded allele frequency; Chr, chromosome; DBP, diastolic
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Table 11. Meta-Analysis of Blood Pressure Responses to Angiotensin Receptor Antagonists
SNP Chr CA NCA N CAF b SE P Value Direction of b (GENRES/GERA II/SOPHIA)
Systolic blood pressure response
rs4953045 2 G A 775 0.26 2.4 0.5 5.1E-07   
rs3814995 19 A G 774 0.32 2.0 0.5 1.5E-05   
rs7086428 10 A G 775 0.37 1.6 0.4 2.1E-04 +  +
rs7597606 2 A G 774 0.41 1.5 0.4 3.2E-04 + + +
rs12814605 12 A G 775 0.14 2.2 0.6 3.5E-04  + 
rs1370555 15 G A 775 0.49 1.3 0.4 2.1E-03   
rs1993802 3 G A 775 0.14 1.9 0.6 2.7E-03  + +
rs711513 7 G A 772 0.37 1.3 0.4 3.1E-03  + 
rs12602832 17 A G 574 0.11 2.1 0.7 4.0E-03  ? 
rs2038912 10 A G 775 0.54 1.1 0.4 9.0E-03 +  +
rs1357365 17 A G 775 0.29 1.1 0.5 1.7E-02 +  +
rs1559557 2 G A 775 0.35 1.1 0.5 1.8E-02 + + 
rs771574 3 G A 775 0.27 1.1 0.5 2.9E-02  + +
rs11841583 13 A G 775 0.09 1.7 0.8 2.9E-02  + +
rs2279989 9 A G 775 0.08 1.6 0.8 3.7E-02  + +
rs17271855 19 A G 775 0.19 1.1 0.5 4.8E-02  + 
rs1432232 2 A C 775 0.23 1.0 0.5 5.0E-02 + 
rs4759885 12 G A 775 0.57 0.7 0.4 9.2E-02  + +
rs1392874 4 A C 775 0.42 0.7 0.4 9.8E-02  +
rs10754459 1 G A 575 0.26 0.7 0.5 1.6E-01  ? +
Diastolic blood pressure response
rs12814605 12 A G 775 0.14 1.9 0.4 6.4E-06   
rs3814995 19 A G 774 0.32 1.4 0.3 1.1E-05   
rs12602832 17 A G 574 0.11 2.1 0.5 4.2E-05  ? 
rs1370555 15 G A 775 0.49 1.1 0.3 1.0E-04  + 
rs1993802 3 G A 775 0.14 1.7 0.4 2.1E-04  + 
rs711513 7 G A 772 0.37 1.1 0.3 2.6E-04  + 
rs2279989 9 A G 775 0.08 1.9 0.5 4.0E-04  + +
rs1357365 17 A G 775 0.29 1.2 0.3 4.5E-04 + + +
rs4953045 2 G A 775 0.26 1.2 0.3 6.0E-04  +
rs2038912 10 A G 775 0.54 1.0 0.3 6.2E-04 +  +
rs1392874 4 A C 775 0.42 1.0 0.3 1.2E-03  +
rs17271855 19 A G 775 0.19 1.2 0.4 2.3E-03  + 
rs7597606 2 A G 774 0.41 0.9 0.3 4.0E-03 + + +
rs11841583 13 A G 775 0.09 1.6 0.6 4.5E-03  + +
rs7086428 10 A G 775 0.37 0.8 0.3 1.3E-02 +  +
rs771574 3 G A 775 0.27 0.8 0.4 1.7E-02  + +
rs10754459 1 G A 575 0.26 0.9 0.4 1.7E-02  ? +
rs4759885 12 G A 775 0.57 0.6 0.3 7.0E-02  + +
rs1559557 2 G A 775 0.35 0.5 0.3 1.6E-01 + 
rs1432232 2 A C 775 0.23 0.5 0.4 2.1E-01 + 
The best GENRES losartan 24-h ambulatory blood pressure response SNPs were analyzed using GENRES, GERA II, and SOPHIA data. ? indicates data not available; CA, coded allele; CAF,
weighed coded allele frequency; Chr, chromosome; N, total number of subjects in meta-analysis; NCA, noncoded allele; SNP, single-nucleotide polymorphism.
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Table 12. Meta-Analysis of Blood Pressure Responses to b-Receptor Blockers
SNP Chr CA NCA N CAF b SE P Value Direction of b (GENRES/PEAR)
Systolic blood pressure response
rs7984003 13 A G 438 0.23 2.9 0.6 7.8E-07 + +
rs2765115 13 G A 440 0.15 3.3 0.7 3.6E-06  
rs6501061 16 G A 440 0.08 4.1 0.9 1.2E-05 + +
rs2514036 11 G A 440 0.14 3.1 0.7 2.1E-05  +
rs2194860 4 A G 440 0.18 2.5 0.6 5.5E-05 + +
rs12967284 18 A G 440 0.28 2.0 0.5 1.1E-04 + +
rs2029870 6 A G 437 0.16 2.5 0.7 2.0E-04  
rs7895038 10 G A 440 0.45 1.8 0.5 2.6E-04  +
rs10519585 5 G A 440 0.32 1.8 0.5 3.7E-04  
rs969981 17 A G 439 0.18 2.2 0.6 3.9E-04  +
rs2506143 10 G A 440 0.12 2.6 0.8 5.5E-04 + +
rs2148117 10 G A 440 0.03 5.1 1.5 8.3E-04  
rs10910862 1 A G 440 0.06 3.5 1.1 1.1E-03  +
rs150210 21 G A 440 0.27 1.7 0.5 1.2E-03  +
rs7268800 20 G A 440 0.40 1.6 0.5 1.2E-03  
rs17642669 5 G A 440 0.06 3.3 1.1 2.4E-03  
rs4357510 1 A C 440 0.06 2.9 1.0 2.6E-03  +
rs11777699 8 G A 439 0.49 1.4 0.5 5.1E-03  
rs1150433 3 A G 440 0.16 1.9 0.7 5.2E-03  +
rs16918900 8 A G 440 0.03 3.7 1.6 2.3E-02  +
Diastolic blood pressure response
rs7268800 20 G A 440 0.40 1.6 0.3 8.6E-07  
rs2506143 10 G A 440 0.12 2.2 0.5 1.0E-05 + +
rs7984003 13 A G 438 0.23 1.7 0.4 1.4E-05 + +
rs12967284 18 A G 440 0.28 1.5 0.4 3.6E-05 + +
rs11777699 8 G A 439 0.49 1.2 0.3 1.2E04  +
rs2029870 6 A G 437 0.16 1.7 0.4 1.6E-04  +
rs17642669 5 G A 440 0.06 2.7 0.7 2.0E-04  +
rs10910862 1 A G 440 0.06 2.6 0.7 2.3E-04  
rs2765115 13 G A 440 0.15 1.8 0.5 2.4E-04  
rs10519585 5 G A 440 0.32 1.2 0.3 3.4E-04  +
rs2514036 11 G A 440 0.14 1.7 0.5 4.4E-04  +
rs1150433 3 A G 440 0.16 1.5 0.5 8.0E-04  
rs4357510 1 A C 440 0.06 2.1 0.7 1.2E-03  +
rs2194860 4 A G 440 0.18 1.4 0.4 1.4E-03 + 
rs6501061 16 G A 440 0.08 2.0 0.6 1.8E-03 + +
rs7895038 10 G A 440 0.45 1.0 0.3 2.5E-03  
rs2148117 10 G A 440 0.03 3.0 1.0 4.0E-03  +
rs16918900 8 A G 440 0.03 3.0 1.1 5.9E-03  +
rs150210 21 G A 440 0.27 0.9 0.4 1.1E-02  +
rs969981 17 A G 439 0.18 1.1 0.4 1.3E-02  +
The best GENRES bisoprolol 24-h ambulatory blood pressure response SNPs were analyzed using GENRES and PEAR data. CA indicates coded allele; CAF, weighed coded allele frequency;
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Table 13. Meta-Analysis of Blood Pressure Responses to Hydrochlorothiazide
SNP Chr CA NCA N CAF b SE P Value
Direction of b (GENRES/
GERA I/PEAR)
Systolic blood pressure response
rs3825926 15 A G 399 0.03 6.7 1.5 5.6E-06 + ? +
rs3799369 6 G A 595 0.11 2.7 0.7 6.6E-05 + + +
rs321329 6 A G 595 0.42 1.8 0.5 7.3E-05   
rs11059985 12 A G 594 0.28 2.0 0.5 1.0E-04 +  +
rs2776906 6 A G 595 0.34 1.8 0.5 1.1E-04 + + +
rs329668 11 A G 398 0.13 2.5 0.7 3.1E-04 + ? +
rs2056531 17 A G 595 0.15 2.2 0.6 8.3E-04 +  +
rs6977301 7 A G 595 0.08 2.7 0.8 1.1E-03 + 
rs4868010 5 A C 594 0.14 2.0 0.7 2.4E-03   
rs776472 7 G A 595 0.43 1.3 0.4 2.6E-03  +
rs17099050 14 C A 595 0.04 3.7 1.2 2.6E-03 +  +
rs964132 19 A G 595 0.04 4.0 1.3 3.0E-03 +  +
rs11006074 10 G A 595 0.14 1.9 0.6 3.2E-03 + + 
rs321320 6 G A 594 0.17 1.7 0.6 5.6E-03  + +
rs4867623 5 A G 398 0.18 1.8 0.7 6.3E-03  ? 
rs3117915 13 G A 595 0.23 1.4 0.5 1.1E-02   
rs1324210 9 A G 595 0.23 1.4 0.5 1.1E-02 + 
rs1553009 7 A G 595 0.16 1.5 0.6 1.7E-02 + 
rs158210 5 A G 595 0.10 1.8 0.7 1.9E-02  + +
rs7821547 8 A G 595 0.23 1.2 0.5 2.4E-02 + 
rs1922117 12 C A 592 0.35 1.0 0.5 2.7E-02  + +
rs6546025 2 G A 595 0.23 0.6 0.5 2.1E-01  + +
Diastolic blood pressure response
rs4867623 5 A G 398 0.18 2.1 0.4 1.5E-06  ? 
rs321329 6 A G 595 0.42 1.5 0.3 2.3E-06   
rs321320 6 G A 594 0.17 1.9 0.4 8.5E-06   
rs4868010 5 A C 594 0.14 1.9 0.4 2.0E-05   
rs2056531 17 A G 595 0.15 1.9 0.5 2.2E-05 +  +
rs964132 19 A G 595 0.04 3.6 0.9 5.8E-05 +  +
rs3825926 15 A G 399 0.03 3.9 1.0 1.2E-04 + ? +
rs11006074 10 G A 595 0.14 1.7 0.4 1.6E-04 + + 
rs3117915 13 G A 595 0.23 1.3 0.4 4.0E-04  + +
rs7821547 8 A G 595 0.23 1.3 0.4 4.5E-04 + 
rs6977301 7 A G 595 0.08 1.9 0.6 6.2E-04 + 
rs17099050 14 C A 595 0.04 2.9 0.9 7.9E-04 +  +
rs776472 7 G A 595 0.43 1.0 0.3 1.1E-03  +
rs1922117 12 C A 592 0.35 1.0 0.3 2.4E-03  + +
rs329668 11 A G 398 0.13 1.4 0.5 2.8E-03 + ? +
rs2776906 6 A G 595 0.34 0.9 0.3 4.1E-03 +  +
rs3799369 6 G A 595 0.11 1.3 0.5 5.5E-03 +  +
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include ALDH3B2 (15 kbp apart) coding for aldehyde dehy-
drogenase 3 family member B2 expressed mainly in salivary
gland and placenta,34 and TBX10 (8 kbp apart) coding for a
member of the T-box family of transcription factors involved in
organogenesis and embryonic development. However,
rs2514036 data were not at all replicated in the PEAR study
using atenolol as the b-blocker (Table 8). In the meta-analysis
combining atenolol data of PEAR, 3 SNPs provided suggestive
associations. rs7984003 and rs7268800 appear to be
intergenic variants, with no obvious candidate genes for BP
regulation in their vicinity, but rs7984003 maps within an
ENCODE transcription factor binding site (ERa_a). rs2765115
is likewise an intergenic variant located 24 kbp from SPATA13
coding for spermatogenesis-associated protein 13, also
known as APC-stimulated guanine nucleotide exchange factor
2 (ASEF2). ASEF2 appears to speciﬁcally activate Rho-family
GTPases and may thus inﬂuence a wide range of cellular
functions, including smooth-muscle contraction. It is also of
interest that a genetic association study has suggested that
SPATA13-AS1 (gene coding for an antisense RNA that
overlaps SPATA13) may serve as a pharmacogenomic predic-
tor of effectiveness of inhaled b-agonists.35
In the meta-analysis of association with hydrochlorothia-
zide responsiveness, 3 different gene loci were identiﬁed
that showed P values <1.09105 when replication data from
GERA I and/or PEAR studies were used (Table 10).
rs3825926 is of interest because the genotype-related b
values for thiazide responses were the highest in both
GENRES and PEAR (Tables 5 and 9); unfortunately, it could
not be analyzed in GERA I. This SNP represents an intronic
variant of ALDH1A3, coding for aldehyde dehydrogenase 1
family member A3. This gene is expressed in a variety of
tissues including retina and kidney, and mutations of
ALDH1A3 are known to result in anophthalmia or microop-
thalmia.36 Another SNP, rs321329, deserves note since
responses to hydrochlorothiazide followed a logical pattern
(although P value remained nonsigniﬁcant in PEAR; Table 9) in
all 3 studies. It should, however, be pointed out that the SNP
rs321329 was not the top SNP of that locus in GENRES and
the top SNP rs321320 showed no evidence of replication in
GERA I or in PEAR (Table 9). The closest candidate genes,
located 90 to 145 kbp from this SNP, include RUNX2,
encoding a transcription factor involved in skeletal morpho-
genesis, and CLIC5, encoding the chloride intracellular
channel protein 5. CLIC5 is expressed (except in placenta
and cochlea) in renal glomerular podocytes and endothelial
cells, and is postulated to function in the maintenance of
glomerular and podocyte architecture.37 It is not known,
however, whether the CLIC5 channel plays any role in thiazide
action.
Certain general delineations of our ﬁndings should be
recapitulated. First, none of the 80 SNPs (20 for each drug)
listed in Tables 2 through 5 proved to give a hit when
compared to the list of >40 hypertension candidate loci6
derived from genome-wide association studies of essential
hypertension. Second, the association of the NPHS1 (nephrin)
gene Glu117Lys variant with losartan responsiveness is of
interest in view of the experimental ﬁndings linking together
angiotensin II levels, angiotensin II receptor blockers, nephrin
expression, and development of albuminuria. Third, 2 different
members of the aldehyde dehydrogenase (ALDH) gene family
got some support as candidate genes, 1 for bisoprolol
(ALDH3B2) and the other for hydrochlorothiazide (ALDH1A3)
responsiveness. The human ALDH gene family contains 19
members.34 It is intriguing that 2 other members of this gene
family (ALDH1A2 and ALDH7) were found to be associated
with the presence of hypertension in African Americans,38 and
yet another member (ALDH2) associated with BP variation in
East Asians.39 ALDHs constitute an important family of
enzymes that are able to oxidize a variety of endogenous and
exogenous aldehydes that play a role in cell proliferation,
differentiation, and responsiveness to environmental stress.34
The links, if any, of ALDHs to regulation of BP and/or
antihypertensive drug action remain unknown at present.
Perspectives
Genomic loci inﬂuencing responsiveness to antihypertensive
drugs are proving difﬁcult to identify, reﬂecting similar
difﬁculties to identify genetic variants underlying elevated
Table 13. Continued
SNP Chr CA NCA N CAF b SE P Value
Direction of b (GENRES/
GERA I/PEAR)
rs1324210 9 A G 595 0.23 0.9 0.4 1.7E-02 + 
rs11059985 12 A G 594 0.28 0.8 0.4 2.1E-02 +  +
rs1553009 7 A G 595 0.16 0.9 0.4 3.3E-02 + 
rs158210 5 A G 595 0.10 1.1 0.5 4.0E-02  + +
The best GENRES hydrochlorothiazide 24-h ambulatory blood pressure response SNPs were analyzed using GENRES, GERA I, and PEAR data. ? indicates data not available; CA, coded
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BP per se. We have carried out a genome-wide analysis of
responses of 4 different antihypertensive drugs using very
carefully designed experimental conditions. Using GENRES
data alone, we could only identify 1 candidate gene locus for
hypertension pharmacogenomics: ACY3 associating with
bisoprolol responsiveness. However, use of replication data
from 3 other trials provided several additional gene candi-
dates, including those coding for nephrin and members of the
aldehyde dehydrogenase family, all of which require additional
studies. We did not ﬁnd evidence for gene loci associating
with responsiveness to more than 1 particular class of
antihypertensive drugs, suggesting that genetic control of
pathways inﬂuencing antihypertensive drug responsiveness
are drug class–speciﬁc. However, since many hypertension
genes may show pleiotropic effects on blood pressure
pathways, it is possible that the power of our study may
simply have been insufﬁcient to detect gene loci interacting
with more than 1 class of drugs. In future, even larger
carefully controlled prospective clinical studies are needed in
which several different antihypertensive drugs are tested. It
should be emphasized that although pharmacogenomic
prediction of antihypertensive response augmentation on
the order of 2 mm Hg may appear minor, in the long term it is
translated into a 7% to 10% lower risk of mortality from
ischemic heart disease and stroke.40 It is realistic to expect
that this level of predictive accuracy in individualized antihy-
pertensive drug therapy could be reached by pharmacoge-
nomic approaches.
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